Table 3: Clinical data from studies with the main multi-target agents in clinical development for the treatment of medullary thyroid cancer.

Author (ref)Pharmaceutical compound 𝑁 Response rate (%)Stabilizations (%)Progression-free survival (months)

Wells Jr. et al. [28]Vandetanib23145Not achieved at 24 months. HR versus placebo = 0.46 𝑃 < 0 . 0 0 1
Kurzrock et al. [29]Cabozantinib374941Not reported
Lam et al. [30]Sorafenib1666217.9
Capdevila et al. [20]Sorafenib34 (15 MTC)474010.5
Schlumberger et al. [31]Motesanib9124811.2
Carr et al. [23]Sunitinib737.5Not reported
De Souza et al. [32]Sunitinib253557Not reported